

BIDiagnostics moves closer to commercialization of debut pet test

3 Mar 2026 - Animal Health | Headline Analysis

BIDiagnostics aims to launch its first companion animal test later this year.

Last year, the Brazilian business secured a contract with an animal *in vitro* diagnostics (IVD) company for the production and commercialization of its first product – the Cat Sporothrix IgG ELISA Kit.

BIDiagnostics founder and chief executive Leila Lopes Bezerra told S&P Global Animal Health the new partner is certified by the Brazilian Ministry of Agriculture and Livestock (MAPA) and has been operating in Brazil for more than 30 years.

She noted: “The production of industrial pilot batches was a critical step and was approved by MAPA in 2025. All stages were successfully completed and the final registration process was submitted.”

BIDiagnostics aims to obtain the final certification to scale up the production and commercialization of the ELISA kit this year. The company is also awaiting approval of an Innovative Research in Small Business grant from the São Paulo Research Foundation. This backing will help with prototyping of the firm’s second product, which will be a point-of-care version of the sporotrichosis test for cats and dogs.

BIDiagnostics was founded in 2019 to build on the [science of glycobiology](#) – the discovery of specific carbohydrates isolated from fungi and, in the near future, other micro-organisms, with a potential application for development of point-of-care diagnostic tests. The firm is looking to tackle several notable emerging zoonotic diseases.

Dr Lopes Bezerra noted BIDiagnostics is also seeking private investment. She pointed out the São Paulo-based company has made “meaningful progress” in the six years since it was founded and surpassed several critical milestones – something that should aid its attempt to raise funding.

Dr Lopes Bezerra stated: “The Brazilian veterinary market is ready and waiting for the commercialization of the first BIDiagnostics’ product.”

However, she suggested the animal health industry needs to be “more open to incorporating innovation and increasing investment in start-ups that have demonstrated the validity of their products in the market”.

Dr Lopes Bezerra explained: “In Latin America, even though there is a clear awareness of the importance of innovation, investments are still timid and, in many cases, they don’t exist at all. Developing an innovative solution for a new zoonotic disease was a strategic decision. This enabled BIDiagnostics to successfully surpass its first critical robustness and performance milestones. Zoonotic sporotrichosis within just a few years, spread from Brazil to several Latin American countries and continues to advance. But the question remains: Is that enough for a start-up to become a truly robust company?”

Analyst Contact Details: Joseph Harvey